Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $15.00 → $10.00 | Outperform → Market Perform | Leerink Partners |
| 4/12/2024 | $21.00 | Buy | BTIG Research |
| 1/8/2024 | Outperform → In-line | Evercore ISI | |
| 5/23/2022 | $12.00 | Outperform | SVB Leerink |
| 3/2/2022 | $10.00 → $11.00 | Underweight | Morgan Stanley |
| 2/24/2022 | $8.00 → $12.00 | Buy | HC Wainwright & Co. |
| 11/5/2021 | $7.00 → $12.00 | Underweight → Neutral | JP Morgan |
| 9/16/2021 | $14.00 → $10.00 | Underweight | Morgan Stanley |
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces
DUBLIN, May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference. A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma
DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, pl